Our Pricing

Affordable Wegovy Monthly Cost from £79.00/Month

Published on: June 03, 2026

Finding affordable Wegovy monthly cost UK options with transparent pricing can be challenging. At Cured Pharmacy, Wegovy (semaglutide) starts from £79.00 per month with no hidden fees—prices are shown upfront before your free online consultation with our UK-registered clinical team. As a GPhC-registered pharmacy (9012511), we dispense only genuine UK-licensed medicines with discreet next-day delivery across the UK.

How Wegovy Works for Weight Management

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone, slowing gastric emptying, reducing appetite signals in the brain, and improving glycaemic control.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. These results represent some of the most significant weight loss outcomes observed in pharmaceutical trials for obesity treatment. The once-weekly subcutaneous injection offers convenience compared to daily alternatives, supporting long-term adherence.

Affordable Wegovy Monthly Cost: What's Included

At Cured Pharmacy, our pricing structure is transparent from the outset. The monthly cost covers your prescribed Wegovy pen, a comprehensive clinical assessment by a UK-registered prescriber, ongoing prescription management, and discreet delivery to your door. Unlike some providers, we display exact prices before you begin your consultation—no surprise fees or membership charges.

Your treatment plan begins with a free online consultation that takes under three minutes to complete. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews your medical history, current medications, and weight management goals to determine if Wegovy is appropriate for you. If prescribed, your medication is dispensed from our UK pharmacy and delivered in 100% discreet packaging.

Dose Escalation and Monthly Costs

Wegovy follows a structured dose escalation schedule to minimise gastrointestinal side effects. Treatment typically begins at 0.25 mg weekly for four weeks, gradually increasing to the maintenance dose of 2.4 mg weekly over 16-20 weeks [2]. Your monthly cost may vary during the escalation phase, as lower starter doses contain different pen configurations. Our clinical team will explain your personalised dosing schedule and associated costs during your consultation, ensuring you understand the full treatment pathway before committing.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms, administration methods, and efficacy profiles. Wegovy represents the current gold standard for pharmacological weight management, but alternatives may be more suitable depending on your clinical circumstances, budget, and lifestyle preferences.

Saxenda (liraglutide) is an earlier GLP-1 receptor agonist requiring daily injections, whilst Mounjaro (tirzepatide) is a newer dual GIP/GLP-1 receptor agonist showing superior weight loss in head-to-head trials [3]. Oral options like Orlistat and Mysimba work through different pathways—lipase inhibition and combined naltrexone-bupropion respectively—but typically produce more modest weight reductions. Your UK prescriber will assess which treatment aligns best with your medical profile and weight management objectives.

Clinical Efficacy: What the Evidence Shows

The STEP clinical trial programme evaluated semaglutide 2.4 mg across diverse patient populations. STEP 2 specifically studied participants with type 2 diabetes, demonstrating an average 9.6% weight reduction alongside improved glycaemic control [2]. STEP 3 combined Wegovy with intensive behavioural therapy, achieving 16.0% average weight loss [2]. These trials consistently showed that semaglutide produces clinically meaningful weight reduction when used as part of a comprehensive programme including dietary modification and increased physical activity.

Who Can Use Wegovy in the UK

Wegovy is licensed for adults with an initial BMI of 30 kg/m² or greater (obese), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [1]. NICE guidelines support GLP-1 receptor agonist use in specialist weight management services for patients meeting these criteria who have not achieved adequate weight loss through lifestyle interventions alone.

Certain medical conditions preclude Wegovy use. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe renal impairment, and pregnancy or breastfeeding [2]. During your consultation, our UK prescribers will review your full medical history, current medications, and any contraindications to ensure Wegovy is safe and appropriate for you. All prescription decisions are made on an individual basis following thorough clinical assessment.

Managing Side Effects and Optimising Results

Gastrointestinal side effects are the most commonly reported adverse events with Wegovy, affecting up to 44% of participants in clinical trials [1]. These typically include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. Most gastrointestinal symptoms are mild to moderate, occur predominantly during dose escalation, and diminish over time as your body adapts to the medication.

To minimise side effects, eat smaller, more frequent meals, avoid high-fat foods, stay well-hydrated, and inject Wegovy at a consistent time each week. If nausea persists, your prescriber may recommend slowing the dose escalation schedule. Rare but serious adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concomitant insulin or sulphonylureas) [2]. Contact your healthcare provider immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction.

Maximising Weight Loss Outcomes

Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating significant weight loss all incorporated lifestyle interventions alongside pharmacotherapy [1][2]. NICE recommends a 600 kcal daily deficit and at least 150 minutes of moderate-intensity aerobic activity per week for adults pursuing weight management. Your prescriber may also recommend referral to specialist dietetic services or structured weight management programmes to optimise your results and support long-term weight maintenance after treatment.

Getting Started with Wegovy at Cured Pharmacy

Beginning your Wegovy treatment journey is straightforward. Complete our free online consultation, which takes under three minutes and covers your medical history, current health status, weight management goals, and any medications you're taking. Our UK-registered clinical team reviews your assessment—usually within 24 hours—and determines whether Wegovy is clinically appropriate for you.

If approved, your prescription is sent electronically to our GPhC-registered pharmacy (9012511), where Superintendent Pharmacist Tarun Kumar and his team dispense your medication. Wegovy is shipped in discreet, unmarked packaging with next-day delivery across the UK. You'll receive clear instructions on injection technique, storage requirements, and what to expect during treatment. Our clinical team remains available for ongoing support throughout your weight management journey, with regular prescription reviews to monitor your progress and adjust treatment as needed.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside pharmacotherapy.